

BIOLOGICAL PRODUCT SUMMARY SHEET

Version: 1.0

Date of First Issue: 9-Aug-20
Revision Date: 9-Aug-20

Covexin® 10

IDENTIFICATION

Organism: *C. perfringens* Type A, *C. perfringens* Type B, *C. perfringens* Type C, *C. perfringens* Type D, *C. sordellii*, *C. novyi* Type B, *C. haemolyticum*, *C. septicum*, *C. tetani*, *C. chauvoei*

Human or Veterinary Use: Covexin® 10

Biological Product Type: Inactivated vaccine

COMPANY INFORMATION

Company Address: Merck & Co., Inc.
126 East Lincoln Ave. P.O. Box 2000,
Rahway, NJ 07065

Emergency Telephone Number: 1-908-423-6000 (24/7/365)

BIOLOGICAL SAFETY HAZARD IDENTIFICATION

Biosafety Risk Group Classification: Risk Group 1

Special circumstances for medical professionals or veterinarians handling live agent (if needed):

Immune Status: No Immune status issues.

Pregnancy: No issues with pregnancy.

Special circumstances for workers handling packaged product (if needed):

Immune Status: No immune status issues.

Pregnancy: No issues with pregnancy.

Medical risk for medical professionals or veterinarians handling live agent (if needed): None

Medical Surveillance for workers handling packaged product (if needed): None

First Aid: In case of accidental self-injection, seek medical advice immediately and show the package insert or label to the physician. Show this document to the consulting physician.

Decontamination:

BIOLOGICAL SAFETY HANDLING INFORMATION

Spills of product: During manufacturing, an infectious agent spill cleanup procedure must be used for culture material prior to the chemical inactivation process. If a procedure is not available, contain material by covering with absorbent material. Minimal personal protective equipment includes safety glasses, lab coat/work uniform, gloves, and slip resistant shoe covers. Cover with paper towels. Soak the towels with freshly prepared dilution (1:10) of bleach (sodium hypochlorite) in tap water. Allow soaked toweling to sit for at least 10 minutes. Carefully gather all waste materials into a plastic bag, then dispose of as infectious waste/ (RMW) via a RMW contract provider.

BIOLOGICAL PRODUCT SUMMARY SHEET

Version: 1.0

Date of First Issue: 9-Aug-20
Revision Date: 9-Aug-20

The final formulated vaccine does not contain live organisms; therefore special biosafety spill procedures are not required. Spill cleanup is to be handled as per departmental SOP. If no SOP available, contain material using a spill pillow or absorbent material and dispose of according to departmental procedures. Soap and water can be used to clean up the area. Minimal personal protective equipment includes safety glasses, lab coat/work uniform, gloves and slip resistant shoe covers.

Shipping Classification Keywords: Infectious Human Infectious Animal CAT A
CAT B GMO

Comments: None

OTHER INFORMATION

References:

1. Covexin® 10 Product Information, http://www.msd-animal-health.co.nz/Products/covexin-10/010_product-overview.aspx, accessed 08/19/2020.

This information in this Biological Product Summary Sheet (BPSS) is a compilation of publicly available information and is correct to the best of our knowledge and belief at the date of its publication.

This is NOT a Safety Data Sheet (SDS) nor is it intended to meet the requirements of an SDS. SDSs convey the hazards of chemicals, not biologicals. Merck is providing this BPSS WITHOUT WARRANTY OR GUARANTEE OF ANY KIND, WHETHER EXPRESSED, IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION ANY AND ALL WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE OR INTELLECTUAL PROPERTY INFRINGEMENT. The information is designed only as a guidance for safe handling, transportation, disposal and release. The information provided relates only to the specific material identified at the top of this BPSS and may not be valid when the BPSS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the BPSS material in the user's product, if applicable.

Questions may be directed to email: EHSDATASTEWARD@merck.com. Reference "Biological Product Summary Sheet Inquiry" in the subject line to ensure your request is appropriately directed. Include the Product Name, Revision Date, BAR ID Number and details of the request in the body of the email.